Phase
Condition
Joint Injuries
Arthritis And Arthritic Pain (Pediatric)
Collagen Vascular Diseases
Treatment
N/AClinical Study ID
Ages 18-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Core Study: Inclusion criteria:
Meeting the American College of Rheumatology (ACR) 1977 preliminary criteria for theclassification of acute arthritis of primary gout
Onset of current acute gout flare within 5 days prior to study entry
Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)
History of ≥ 3 gout flares within the 12 months prior to study entry
Contraindication, intolerance, or lack of efficacy for non-steroidal anti-inflammatorydrugs (NSAIDs) and/or colchicine
Exclusion
Exclusion criteria:
Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or otheracute inflammatory arthritis
Presence of severe renal function impairment
Use of specified pain relief medications or biologics ( corticosteroids, narcotics,paracetamol/acetominophen, ibuprofen, colchicine, IL-blocker, and tumor necrosisfactor inhibitor) within specified periods prior to study entry
Live vaccinations within 3 months prior to randomization
Requirement for administration of antibiotics against latent tuberculosis (TB)
Refractory heart failure (Stage D)
Unstable cardiac arrhythmias or unstable symptomatic coronary ischemia
Any active or recurrent bacterial, fungal, or viral infection Extension Study 1: Inclusion Completion of the Core study. A patient was defined as completing the core studyif they completed the study up to and including visit 7. Exclusion
Continuation in this extension study was considered inappropriate by the treatingphysician. Extension Study 2: Inclusion Completed of the first extension study CACZ885H2356E1. A patient was defined ascompleting the first extension study if they completed the study up to and including Visit 10). Exclusion
-Continuation in this extension study was considered inappropriate by the treatingphysician Other protocol-defined inclusion-exclusion criteria applied to the core and extensionstudies.
Study Design
Study Description
Connect with a study center
Novartis Investigative Site
Darlinghurst, New South Wales
AustraliaSite Not Available
Novartis Investigative Site
Fitzroy, Victoria
AustraliaSite Not Available
Novartis Investigative Site
Heidelberg, Victoria
AustraliaSite Not Available
Novartis Investigative Site
Daw Park SA,
AustraliaSite Not Available
Novartis Investigative site
Gozee,
BelgiumSite Not Available
Novartis Investigative Site
Mount Pearl, Newfoundland and Labrador
CanadaSite Not Available
Novartis Investigative site
St-John's, Newfoundland and Labrador
CanadaSite Not Available
Novartis Investigative site
Hamilton, Ontario
CanadaSite Not Available
Novartis Investigative site
Barranquilla,
ColombiaSite Not Available
Novartis Investigative site
Bogota,
ColombiaSite Not Available
Novartis Investigative site
Bucaramanga,
ColombiaSite Not Available
Novartis Investigative site
Parnu,
EstoniaSite Not Available
Novartis Investigative site
Tallinn,
EstoniaSite Not Available
Novartis Investigative site
Tartu,
EstoniaSite Not Available
Novartis Investigative Site
Bayreuth,
GermanySite Not Available
Novartis Investigative Site
Berlin,
GermanySite Not Available
Novartis Investigative Site
Leipzig,
GermanySite Not Available
Novartis Investigative Site
Loehne,
GermanySite Not Available
Novartis Investigative Site
Magdeburg,
GermanySite Not Available
Novartis Investigative site
Munich,
GermanySite Not Available
Novartis Investigative Site
Guatemala City,
GuatemalaSite Not Available
Novartis Investigative Site
Riga,
LatviaSite Not Available
Novartis Investigative Site
Valmiera,
LatviaSite Not Available
Novartis Investigative Site
Kaunas,
LithuaniaSite Not Available
Novartis Investigative Site
Kedainiai,
LithuaniaSite Not Available
Novartis Investigative site
Klaipeda,
LithuaniaSite Not Available
Novartis Investigative Site
Siauliai,
LithuaniaSite Not Available
Novartis Investigative Site
Vilnius,
LithuaniaSite Not Available
Novartis Investigative site
Culiacan,
MexicoSite Not Available
Novartis Investigative site
Guadalajara,
MexicoSite Not Available
Novartis Investigative site
Mexicali,
MexicoSite Not Available
Novartis Investigative site
Oslo,
NorwaySite Not Available
Novartis Investigative site
Katowice,
PolandSite Not Available
Novartis Investigative site
Kutno,
PolandSite Not Available
Novartis Investigative site
Lublin,
PolandSite Not Available
Novartis Investigative Site
Wroclaw,
PolandSite Not Available
Novartis Investigative site
Chelyabinsk,
Russian FederationSite Not Available
Novartis Investigative site
Ekaterinburg,
Russian FederationSite Not Available
Novartis Investigative site
Moscow,
Russian FederationSite Not Available
Novartis Investigative site
Petrozavodsk,
Russian FederationSite Not Available
Novartis Investigative Site
St. Petersburg,
Russian FederationSite Not Available
Novartis Investigative site
Tula,
Russian FederationSite Not Available
Novartis Investigative site
Tver,
Russian FederationSite Not Available
Novartis Investigative site
Yaroslavl,
Russian FederationSite Not Available
Novartis Investigative site
Yekaterinburg,
Russian FederationSite Not Available
Novartis Investigative site
Singapore,
SingaporeSite Not Available
Novartis Investigative Site
Goeteborg,
SwedenSite Not Available
Novartis Investigative site
Stockholm,
SwedenSite Not Available
Novartis Investigative Site
Lausanne,
SwitzerlandSite Not Available
Novartis Investigative site
Adana,
TurkeySite Not Available
Novartis Investigative site
Ankara,
TurkeySite Not Available
Novartis Investigative site
Etlik,
TurkeySite Not Available
Novartis Investigative Site
Manisa,
TurkeySite Not Available
Novartis Investigative Site
Donetsk,
UkraineSite Not Available
Novartis Investigative Site
Kyiv,
UkraineSite Not Available
Novartis Investigative Site
Lviv,
UkraineSite Not Available
Novartis Investigative Site
Zaporizhzhya,
UkraineSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.